Yisheng Jiankang and SATOL Launch Define 'Precision Micro-Diagnostics' to Build a Closed-Loop Endocrine Health Management System for Women
Home-based testing is an emerging blue ocean in health management, but it has yet to achieve large-scale adoption due to limitations in the variety of test items, ease of operation, user acceptance, and testing accuracy. To expand the range of tests available in home settings and promote widespread use of home-based testing, more precise, minimally invasive, and convenient solutions are needed.
On August 25, 2022, SATOL, a public welfare platform initiated by the World Life Science and Technology Conference, partnered with Yisheng Jiankang to jointly host the first online live broadcast of SATOL.“In the Era of Big Health: Innovation and Leap in Home-Based Precision Micro-Testing”。
This event centered on precision micro-testing technology for home use. At the conference, Zhou Jianhong, Chief Physician of Gynecology at the Women’s Hospital, School of Medicine, Zhejiang University; one of the founders of the Chinese Branch of the International Society of Gynecological Endocrinology; and Chair of the Menopause Healthcare Committee of the China Association for Maternal and Child Health Studies, elaborated in detail on the urgent need for prevention and health management of endocrine disorders in women. Yang Weiping, Chief Scientist at Yisheng Jiankang, highlighted the high value of precision micro-testing technology in home-based testing scenarios.
Addressing the needs for prevention and health management of endocrine disorders in women, Wang Qiangyu, Founder and CEO of Yisheng Jiankang, unveiled the company’s first product at the conference, leveraging precision micro-detection technology.“Ovarian Health Assessment”, will provide endocrine at-home testing and health management services to 100 million women.
The endocrine system is the most critical regulatory system in the human body, playing a vital role in growth and development, reproduction, metabolism, and the maintenance of internal homeostasis. Under normal physiological conditions, various hormones in the body remain in a state of dynamic equilibrium; deviations in hormone levels, whether elevations or reductions, can lead to various endocrine disorders.
Female reproductive endocrine disorders are the most common gynecological conditions, primarily caused by abnormalities in the hypothalamic-pituitary-ovarian (HPO) axis and occurring throughout a woman’s entire lifespan. In recent years, influenced by environmental factors, diet, and lifestyle habits, the incidence of gynecological endocrine disorders has been gradually increasing. Relevant data report that the annual prevalence of abnormal uterine bleeding among women aged 18–50 is 53‰; up to 80% of perimenopausal women experience hot flashes, but only 20%–30% seek medical attention; approximately 8%–13% of women may have polycystic ovary syndrome (PCOS), imposing a substantial disease burden.
Simply put, the ovaries not only affect female reproductive function, leading to infertility, but may also cause diseases in target organs or systems due to declined endocrine function. Therefore, it is urgent to prevent female endocrine disorders.
Director Zhou Jianhong stated, “Prevention of endocrine disorders in women has garnered a certain degree of attention, and related research is being vigorously conducted across China. Some Grade 3A hospitals have established departments of gynecologic endocrinology; however, the field remains in an exploratory phase, and it is premature to speak of tangible outcomes.”
Women’s insufficient awareness of endocrine disease prevention, the need to strengthen health education and its dissemination, strained hospital medical resources, and the fact that most gynecologists remain focused on treatment rather than prevention—all these constitute barriers to implementing preventive measures for endocrine diseases in women.
Director Zhou Jianhong concluded:"The key to preventing endocrine disorders in women lies in proactive health management."Health monitoring is only the first step; follow-up medical guidance from a professional team of physicians, based on the test results, is required to help users manage their endocrine health.
Home-based testing is a new direction in aiding the prevention of endocrine disorders in women.Previously, women had to spend considerable time registering and queuing for medical consultations, often requiring half a day or even an entire day at the hospital. With home-based testing, users can obtain test results at home, which not only saves time and offers greater convenience but also conserves medical resources in hospitals.
Director Zhou Jianhong is highly optimistic about the prospects of home-based testing in the prevention of female endocrine disorders. “For instance, patients with premature ovarian insufficiency and polycystic ovary syndrome require prolonged treatment courses that combine pharmacological therapy with lifestyle interventions. During treatment, regular monitoring of the six key reproductive hormones and anti-Müllerian hormone (AMH) levels is essential. These conditions are well-suited for home-based care; leveraging home testing kits, patients can perform tests themselves at home and obtain health guidance via online platforms, thereby eliminating the need for frequent hospital visits.”
Regarding the prospects of home testing in women's endocrine health, Director Zhou stated,Home-based testing requires clarity on three key issues: who is suitable for home-based testing, what is the appropriate testing frequency, and how to provide corresponding medical guidance after testing.only then can the full potential of at-home testing be realized.
“The next decade is a critical period for China to achieve the ‘Healthy China 2030’ goals, and the field of maternal and child health in China is transitioning from a focus on ‘survival’ to an emphasis on ‘quality of life.’ ‘Maternal and child health for all’ and ‘all for maternal and child health’ should become a national consensus, and the importance of preventing endocrine disorders in women deserves attention from everyone.”
Following the wave of at-home COVID-19 antigen self-testing in 2022, the value and advantages of home-based testing have become widely recognized. Director Zhou Jianhong stated, “Although the application of home-based testing in female endocrine disorders is still in an exploratory phase, it is undoubtedly the trend of the future.”
Dr. Yang Weiping, Chief Scientist at Yisheng Jiankang, believes that home-based testing remains a niche segment and has yet to achieve widespread adoption, primarily due to the limitations of current home-testing models, necessitating technological innovation as a priority.
Currently, the common home-based testing models on the market are divided into two categories: POCT-based self-testing at home, and home sample collection with samples sent for laboratory testing.
POCT products enable the entire process—from sample collection and testing to result interpretation—to be completed in a home setting, including early pregnancy test strips, diabetes monitoring, and blood pressure testing. The range of detectable parameters for these products is highly limited. Furthermore, since sample collection, testing, and result interpretation are all performed by users themselves, a certain level of medical knowledge is required. However, most users lack sufficient medical expertise, making it difficult for them to accurately interpret the significance of test results and implement targeted health management.
Home-based sampling and sample submission model was already born in the 1970s, initially provided as a service by insurance companies. This model transfers traditional testing techniques to home settings, requiring professional medical personnel to visit for blood collection. The large volume of samples collected results in high costs, making it difficult to promote on a large scale.
Yisheng Jiankang believes that,Micro-sampling + Precise Testing + Health Management Guidance: A Breakthrough in Addressing the Current Pain Points of At-Home Testing
First, to address the demand for convenience, minimal invasiveness, painlessness, and precision in home-based settings, Yisheng Jiankang has developed“Precision Micro-detection Technology”。
Dr. Yang Weiping stated that precision micro-detection technology has threefold implications.
First is “Precision”, home test results must achieve medical-grade accuracy, which is the lifeline of home testing products;Second, “trace amounts”, medical institutions typically collect larger sample volumes, and the sampling process is relatively cumbersome. Home-testing users have high expectations for sampling convenience and experience, requiring minimally invasive, painless, and micro-volume sample collection;Third, “micro-projects”, since micro-samples cannot undergo hundreds of tests as performed by professional medical institutions, it is necessary to carefully select appropriate items that can accurately reflect human health status.
Yisheng Jiankang, specially developed for home-use scenariosPrecision Micro-Detection Technology, in the sampling process, through the originalMicro-Volume Peripheral Blood Collection Device, achievedMinimally Invasive, Minimally Sensing, and Simple Peripheral Blood Sampling, eliminating the need for cumbersome venous blood collection. “Furthermore, many indicators require quantitative testing, making the accuracy of sample volume critical; otherwise, it may lead to testing errors. We have inventedCapillary Quantitative Method, capable ofPrecisely collect 50 microliters of capillary blood, with an error margin not exceeding 5%."During transportation, Yisheng Jiankang's sample preservation and drying technology ensures the stability of analytes at ambient temperature, eliminating the need for cold chain logistics."
Yisheng Health has been validated in thousands of individuals. Data indicate that the test results from dried blood spots prepared from capillary blood developed by Yisheng Jiankang, after elution, are largely consistent with those from venous plasma, with correlations for all parameters exceeding 0.93.
By integrating precision micro-testing technology with artificial intelligence, Yisheng Jiankang has established a closed-loop system for precise at-home testing and health management. This enables the rapid deployment of projects such as female endocrine disorder testing in home settings, thereby driving a leap forward in China’s at-home testing market.
Yang Weiping concluded, “Precision micro-testing technology meets the requirements of home-based testing for minimal sample volumes and high accuracy. Meanwhile, heightened health awareness among residents and breakthroughs in artificial intelligence have opened up significant possibilities for substantial advancements in home-based testing.”Home-based testing has met the conditions for a qualitative leap driven by quantitative accumulation."In the future, home-based testing will become an essential requirement for residents' health management."
Addressing the urgent need for prevention of female endocrine disorders, Yisheng Jiankang unveiled its first product at the conference.“Ovarian Health Assessment”Product: Designed for women aged 18–35, it helps them comprehensively assess their ovarian reserve function, provides early warnings of health risks, and offers interpretation along with appropriate intervention services.
The core biomarker for “Ovarian Health Assessment” is Anti-Müllerian Hormone (AMH). AMH levels closely mirror the trajectory of ovarian aging, making it the earliest hormone to change with advancing age. It accurately reflects a woman’s ovarian reserve and provides a better assessment of age-related decline in fertility. Dr. Zhou Jianhong stated, “Ovarian function significantly influences the onset and progression of endocrine disorders in women and is closely linked to conditions such as ovarian aging and polycystic ovary syndrome (PCOS). Furthermore, since AMH levels are not affected by the menstrual cycle, combining them with age factors allows for a more accurate evaluation of ovarian health.”
Clinically, the standard practice is to perform a six-panel hormone test. As an out-of-pocket expense, anti-Müllerian hormone (AMH) testing has not yet been widely adopted, and public education on ovarian health remains inadequate, lagging behind HPV screening and breast examinations. In the home-testing scenario, AMH testing is virtually nonexistent. Recognizing the critical importance of ovarian health to women’s physical and mental well-being, Yisheng Jiankang has launched “Ovarian Health Assessment” as its inaugural product, aiming to address the gaps in domestic AMH testing availability and awareness of ovarian health.
Leveraging precision micro-detection technology, Yisheng Jiankang employs a globally proprietary micro-quantitative capillary blood collection device to resolve the challenge of quantitative collection from minute samples. This enables precise 50-microliter sampling, ensuring the accuracy, convenience, and accessibility of at-home AMH testing. Furthermore, Yisheng Health’s strategic layout extends beyond diagnostics to encompass comprehensive health management services across the entire life cycle.
Wang Qiangyu, the company's founder and CEO, stated: "Users can enjoy“One Test, Lifelong Management”. The company collaborates with leading clinical experts to provide easy-to-understand test reports, and is equipped with health consultants who create healthy lifestyle guidance for users from multiple dimensions such as dietary nutrition, exercise prescriptions, and lifestyle habits.Full Life-Cycle Closed-Loop Management of Ovarian Health, ensuring women's endocrine health."
Centered on its “Ovarian Health Assessment” product, Yisheng Jiankang will launch major commercial initiatives across the consumer (C-end), business (B-end), and healthcare provider (small H-end) segments, while also strengthening public education on ovarian health and actively collaborating with major social media platforms.
Wang Qiangyu stated that at-home COVID-19 antigen testing triggered an explosion in the overseas home testing market. China’s home testing market is still in its early stages, with significant untapped potential. He expressed optimism about the potential of single-disease home testing, including tests for female endocrine disorders, thyroid hormones, Helicobacter pylori, and early screening for colorectal cancer.
In the future, targeting ovarian health, Yisheng Jiankang will launch a “Fertility Reserve Capacity Assessment” product for career women aged 25–40 with family planning intentions, and an “Ovarian Decline Assessment” product for women over 35 experiencing anxiety about premature ovarian insufficiency, thereby addressing the personalized needs of women across different age groups for ovarian health management.
Click the link to watch the replay of the live broadcast “Innovation and Transformation in Precise Home Micro-Testing in the Era of Big Health”:http://sv.shulan.com/watch/10819364